About Faricimab
            
            Class: | Anti-VEGF (Vascular Endothelial Growth Factor) and Angiopoietin-2 inhibitor  
Use: | Treatment of neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME)  
Adult dose: | Initial: 6 mg (0.05 mL) via intravitreal injection once every 4 weeks for the first 4 doses, followed by one injection every 8 to 16 weeks based on disease activity  
Pediatric dose: | Safety and efficacy not established in pediatric patients  
Side effects: | Conjunctival hemorrhage, e
         
        
            
                
                
                    
                        Drug Class
                    
                    Anti-VEGF (Vascular Endothelial Growth Factor) and Angiopoietin-2 inhibitor
                 
                
                
                    
                        Uses & Indications
                    
                    Treatment of neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME)
                 
                
                
                    
                        Storage Requirements
                    
                    Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light.
                 
                
                
                    
                        Manufacturer & Packaging
                    
                    
                        Manufacturer: F.Hoffmann - La Roche Ltd[Basel;Switzerland], Switzerland
                    
                    
                    Package Size
                    1 Glass Vial + 1 Transfer filter needle
                    
                    
                    Price & Supplier
                    
                        Price in UAE: AED 4797.00
                    
                    
                 
             
            
                
                
                    
                        Dosage Information
                    
                    
                        Adult Dose
                    
                    
                        Initial: 6 mg (0.05 mL) via intravitreal injection once every 4 weeks for the first 4 doses, followed by one injection every 8 to 16 weeks based on disease activity
                    
                    
                        Pediatric Dose
                    
                    
                        Safety and efficacy not established in pediatric patients
                    
                 
                
                
                    
                        Side Effects
                    
                    Conjunctival hemorrhage, eye pain, vitreous floaters, increased intraocular pressure, and retinal pigment epithelial tear
                 
             
         
        
        
            
                Contraindications & Precautions
            
            Ocular or periocular infections, active intraocular inflammation, hypersensitivity to faricimab or any of its components
         
        
        
            
                Important Warnings
            
            Risk of endophthalmitis and retinal detachment; monitor for signs of infection or inflammation. Use with caution in patients with a history of stroke or myocardial infarction.
         
        
        
        
        
        
        
        
        
            
                Medical Disclaimer
            
            
                This information is for educational purposes only and should not replace professional medical advice. 
                Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. 
                The information presented here is specific to medicines available in UAE pharmacies and is regularly updated 
                to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.